T Cell News and Research

Latest T Cell News and Research

Scientists identify biological mechanism that may be responsible for icy extremities

Cold feet-those chilly appendages that plague many people in the winter and an unlucky few all year round-can be the bane of existence for singles and couples alike. In a new study, scientists led by Selvi C. Jeyaraj of the Research Institute at Nationwide Children's Hospital have identified a biological mechanism that may be responsible for icy extremities: an interaction between a series of molecules and receptors on smooth muscle cells that line the skin's tiny blood vessels.

1 Aug 2012

Flightless molecule may help control spread of cancer from one tissue to another

Thanks to the "flightless" molecule, the spread of cancer from one tissue to another may one day be grounded. In a new report published in the August 2012 print issue of The FASEB Journal, laboratory experiments show that "flightless" (named after its effects on fruit flies) increases the "stickiness" that causes cells, including cancer cells, to attach to underlying tissue, which in turn, slows their movement throughout the body.

1 Aug 2012

Miami Project to Cure Paralysis receives FDA permission to begin Phase 1 trial

The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.

1 Aug 2012

Scientists decode stability blueprint of rhomboid enzyme

Johns Hopkins scientists have decoded for the first time the "stability blueprint" of an enzyme that resides in a cell's membrane, mapping which parts of the enzyme are important for its shape and function.

1 Aug 2012

RBC transfusion use in neonates requires more study

Results from a systematic review indicate that the safety and efficacy of red blood cell transfusions in neonates is currently unclear and requires more precise study.

1 Aug 2012

Orc1 mutations may explain pathology in manifestations of Meier-Gorlin syndrome

Research published Aug. 1 by scientists at Cold Spring Harbor Laboratory (CSHL) links gene mutations found in some patients with Meier-Gorlin syndrome (MGS) with specific cellular dysfunctions that are thought to give rise to a particularly extreme version of dwarfism, small brain size, and other manifestations of abnormal growth which generally characterize that rare condition.

1 Aug 2012

Stemgent acquires Asterand’s Human Tissue Business for $9 million

Stemgent, Inc. announced today that it has completed the acquisition of Asterand Plc's Human Tissue Business for $9 million. Asterand provides a set of high quality, human-tissue based tools for drug and drug target discovery that is highly complementary to Stemgent's growing portfolio of innovative research products and services to advance cellular reprograming and stem cell research.

1 Aug 2012

Researchers discover new approach to treat two lethal metastatic cancers

A potentially powerful new approach to treating two lethal metastatic cancers - triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer - has been discovered by researchers at Mayo Clinic in Florida.

1 Aug 2012

Chk1 gene alone is sufficient to kill cancer cells

Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.

1 Aug 2012

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.

1 Aug 2012

Scientists discover novel therapeutic target for advanced breast cancer

Scientists at Western University have identified a new therapeutic target for advanced breast cancer which has shown tremendous promise in mouse models.

1 Aug 2012

Freiburg scientist receives ERC Starting Grant for NutrImmune project

The microbiologist and immunologist Prof. Dr. Andreas Diefenbach, Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Centre, has been awarded a European Research Council "Starting Grant" for his project "NutrImmune". The ERC Starting Grant is one of Europe's most prestigious grants for young investigators.

1 Aug 2012

New drug may be useful in treating long QT syndrome

Johns Hopkins researchers have discovered a new drug that may be useful in treating a heart rhythm condition called long QT syndrome.

1 Aug 2012

Life Technologies second quarter revenue increases 1% to $950 million

Life Technologies Corporation today announced results for its second quarter ended June 30, 2012.

31 Jul 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Population Genetics validates GenomePooling™ for cancer

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

31 Jul 2012

Researchers use computational analysis to identify new Achilles heel for drug-resistant breast cancer

Researchers have used computational analysis to identify a new Achilles heel for the treatment of drug-resistant breast cancer. The results, which are published in Molecular Systems Biology, reveal that the disruption of glucose metabolism is an effective therapeutic strategy for the treatment of tumours that have acquired resistance to front-line cancer drugs such as Lapatinib.

31 Jul 2012